Augmentation of Ca2+-induced microsomal triglyceride transfer protein activity by glucose supply enhances hypertriglyceridemia in vivo

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 5, 2006, Pages 889-895

  Cho, Hyun Jeong ^a   Kang, Hyo Chan ^a   Ju, Young Cheol ^a   Lee, Hyun Sub ^a   Kim, Hyeong Soo ^a   Park, Hwa Jin ^a  

^a Inje University   (South Korea)

Author keywords

Apolipoprotein B; Ca2+; Glucose; Microsomal triglyceride transfer protein; Triglyceride

Indexed keywords

CALCIUM; CALCIUM CHELATING AGENT; CALMODULIN INHIBITOR; CARRIER PROTEIN; EDETIC ACID; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; GLUCOSE; INSULIN; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; 1,2-BIS(2-AMINOPHENOXY)ETHANE-N,N,N',N'-TETRAACETIC ACID; APOLIPOPROTEIN B; CALMODULIN; CHELATING AGENT; DRUG DERIVATIVE; EGTAZIC ACID; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG EFFECT; FOOD INTAKE; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; INSULIN BLOOD LEVEL; LIVER CELL; MALE; NONHUMAN; PROTEIN ASSEMBLY; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RAT; ANIMAL; BLOOD; CELL CULTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CULTURE MEDIUM; DRUG ANTAGONISM; EATING; LIPID METABOLISM; LIVER; LIVER MICROSOME; METABOLISM; SPRAGUE DAWLEY RAT; STIMULATION;

ANIMALS; APOLIPOPROTEINS B; CALCIUM; CALMODULIN; CARRIER PROTEINS; CELLS, CULTURED; CHELATING AGENTS; CULTURE MEDIA; EATING; EGTAZIC ACID; GLUCOSE; HEPATOCYTES; HYPERTRIGLYCERIDEMIA; INSULIN; LIPID METABOLISM; LIVER; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; STIMULATION, CHEMICAL; SULFONAMIDES;

EID: 33646450768     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.889     Document Type: Article

References (34)

1. Shelness G. S., Ingram M. F., Huang X. F., DeLozier J. A., J. Nutr., 129, 245s-462s (1999).
2. Rustaeus S., Lindberg K., Stillemark P., Claesson C., Asp L., Larsson T., Boren J., Olofsson S. O., J. Nutr., 129, 463s-466s (1999).
3. Gordon D. A., Jamil H., Biochim. Biophys. Acta, 1486, 72-83 (2000).
4. Nossen J. O., Rustan A. C., Drevon C. A., Biochem. J., 247, 433-439 (1987).
5. Kwong T. C., Sparks J. D., Pryce D. J., Cianci J. F., Sparks C. E., Biochem. J., 263, 411-415 (1989).
6. Hayashi K., Gohda M., Matzno S., Kubo Y., Kido H., Yamauchi T., Nakamura N., J. Pharmacol. Exp. Ther., 282, 882-890 (1997).
7. Björnsson O. G., Bourgeois C. S., Gibbons G. F., Eur. J. Clin. Invest., 28, 720-729 (1998).
8. Björnsson O. G., Sparks J. D., Sparks C. E., Gibbons G. F., J. Lipid Res., 33, 1017-1027 (1992).
9. Cho H. J., Kang H. C., Choi S. A., Ju Y. C., Lee H. S., Park H. J., Biol. Pharm. Bull., 28, 1418-1423 (2005).
10. Bacon B., Farahvash M., Janney C., Neuschwander-Tetri B., Gastroenterology, 107, 1103-1109 (1994).
11. Atzel A., Wetterau J. R., Biochemistry, 33, 15382-15388 (1994).
12. Taghibiglou C., Carpentier A., Inderstine S. C. V., Chen B., Rudy D., Aiton A., Lewis G. F., Adeli K., J. Biol. Chem., 275, 8416-8425 (2002).
13. Yang L. Y., Kuksis A., Myher J. J., Steiner G., J. Lipid Res., 37, 262-274 (1996).
14. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J., J. Biol. Chem., 193, 265-275 (1951).
15. Berry M. N., Friend D., J. Cell Biol., 43, 506-520 (1969).
16. Wetterau J. R., Aggerbeck L. P., Bouma M.-E., Eisenberg C., Munck A., Hermier M., Schmitz J., Gay G., Rader D. J., Gregǧ R. E., Science, 258, 999-1001 (1992).
17. Moor L., Biochem. Pharmacol., 29, 2505-2511 (1980).
18. Hidaka H., Tanaka T., "Biopharmacological Assessment of Calmodulin Function: Utility of Calmodulin Antagonists," ed. by Kakiuchi H., Hidaka H., Means A. R., Plenum Press, New York, 1982, pp. 19-33.
19. Gordon P. B., Holen I., Foss M., Røtnes J. S., Seglen P. O., J. Biol. Chem., 268, 26107-26112 (1993).
20. Marcos E., Mazur A., Cardot P., Rayssiguier Y., Lipids, 25, 575-577 (1990).
21. Brown A. M., Wiggins D., Gibbons G. F., Arterioscler. Thromb. Vasc. Biol., 19, 321-329 (1999).
22. Hidaka H., Yamaki T., Totsuka T., Asano M., Mol. Pharmacol., 15, 49-59 (1979).
23. Laker M. E., Mayes P. A., Biochim. Biophys. Acta, 795, 427-430 (1984).
24. Topping D. L., Mayes P. A., Biochem. J., 126, 295-311 (1972).
25. Komatsu M., Yajima H., Yamada S., Kaneko T., Sato Y., Yamauchi K., Hashizume K., Aizawa T., Diabetes, 48, 1543-1549 (1999).
26. Hedeskov C. J., Physiol. Rev., 60, 442-509 (1980).
27. Wolheim C. J., Sharp G. W., Physiol. Rev., 61, 914-973 (1981).
28. Williamson J. R., Monck J. R., Annu. Rev. Physiol., 51, 107-124 (1989).
29. Takagi H. (ed.), "Catalogs of Japan SLC Experimental Animals," Japan SLC Inc., 1998, p. 1.
30. Taskinen M. R., Packard C. J., Shepherd J., Diabetes, 39, 1017-1027 (1990).
31. Gibbons G. F., Clin. Sci., 71, 477-486 (1986).
32. Howard B. V., Curr. Opin. Lipidol., 5, 216-220 (1994).
33. Boogaerts J. R., Malone-McNeal M., Archambault-Schexnayder J., Davis R. A., Am. J. Physiol., 246, E77-E83 (1984).
34. Lee R. S., "Omega-3 Fatty Acid in Health and Disease," ed. by Lee R. S., Karl M. K., Marcel Dekker, New York, 1990, pp. 1-56.